Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99915 | 0.93 | MTNR1A (0.42) | PTPN1MTNR1AMTNR1BNR1H2NR1H3 | |
| SCHEMBL101537 | 0.90 | PTPN1 (0.45) | PTPN1MTNR1AMTNR1BNR1H2NR1H3 | |
| SCHEMBL99719 | 0.82 | MTNR1A (0.42) | PTPN1MTNR1AMTNR1BNR1H2NR1H3 | |
| SCHEMBL1094441 | 0.79 | MTNR1A (0.36) | MTNR1AMTNR1BNR1H2NR1H3FFAR1 | |
| SCHEMBL1380801 | 0.77 | TDP1 (0.61) | FFAR1TDP1 | |
| SCHEMBL7591321 | 0.77 | MTNR1A (0.39) | MTNR1AMTNR1BNR1H2NR1H3BACE1 | |
| SCHEMBL15822278 | 0.76 | ALOX5 (0.51) | PTPN1TDP1 | |
| Hydrochloric Acid SCHEMBL7594650 | 0.76 | MTNR1A (0.39) | MTNR1AMTNR1BNR1H2NR1H3BACE1 | |
| SCHEMBL1068886 | 0.76 | CYP4F2 (0.38) | MTNR1AMTNR1BNR1H2NR1H3APP | |
| SCHEMBL1905729 | 0.76 | NPC1 (0.41) | MTNR1AMTNR1BNR1H2NR1H3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | PTPN1 2109/4885MTNR1A 430/4885MTNR1B 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.